Opportunistic Infections Citation List:
January 20 - February 2, 2010
OPPORTUNISTIC PROTOZOA COMPOUNDS (including pneumocystis, cryptosporidium, toxoplasma, microsporidia [encephalitozoon, enterocytozoon, vittaforma])
1. Original quinazoline derivatives displaying antiplasmodial properties. Kabri, Y., N. Azas, A. Dumetre, S. Hutter, M. Laget, P. Verhaeghe, A. Gellis, and P. Vanelle. Eur J Med Chem. 45(2): p. 616-22; PMID[19926173].
[Pubmed]. OI_0121-020410.
ANTIFUNGAL COMPOUNDS ( includes Cryptococcus, Aspergillus, Candida, & Histoplasma)
2. Effects of Combined Addition of Atovaquone and Lithium on the in Vitro Cell Growth of Pathogenic Yeast Candida albicans. Minagawa, N., M. Uehara, S. Seki, A. Nitta, and K. Kogawara. Yakugaku Zasshi. 130(2): p. 247-51; PMID[20118649].
[Pubmed]. OI_0121-020410.
3. Inhibition of Candida albicans growth by brominated furanones. Duo, M., M. Zhang, Y.Y. Luk, and D. Ren. Appl Microbiol Biotechnol. 85(5): p. 1551-63; PMID[19756586].
[Pubmed]. OI_0121-020410.
4. In vitro antifungal activity of the berberine and its synergism with fluconazole. Iwazaki, R.S., E.H. Endo, T. Ueda-Nakamura, C.V. Nakamura, L.B. Garcia, and B.P. Filho. Antonie Van Leeuwenhoek. 97(2): p. 201-5; PMID[19882381].
[Pubmed]. OI_0121-020410.
ANTIBACTERIAL COMPOUNDS (includes Mycobacterium spp., Drug Resistant, MAC, MDR)
5. A microwave-assisted, facile, regioselective Friedlander synthesis and antitubercular evaluation of 2,9-diaryl-2,3-dihydrothieno-[3,2-b]quinolines. Balamurugan, K., V. Jeyachandran, S. Perumal, T.H. Manjashetty, P. Yogeeswari, and D. Sriram. Eur J Med Chem. 45(2): p. 682-8; PMID[19944499].
[Pubmed]. OI_0121-020410.
6. Novel Proteasome Inhibitors as Potential Drugs to Combat Tuberculosis. Cheng, Y. and J. Pieters. J Mol Cell Biol. [Epub ahead of print]; PMID[20123700].
[Pubmed]. OI_0121-020410.
7. Design and synthesis of some new quinoline-3-carbohydrazone derivatives as potential antimycobacterial agents. Eswaran, S., A.V. Adhikari, N.K. Pal, and I.H. Chowdhury. Bioorg Med Chem Lett. 20(3): p. 1040-1044; PMID[20056418].
[Pubmed]. OI_0121-020410.
8. QSAR Modeling of a Set of Pyrazinoate Esters as Antituberculosis Prodrugs. Fernandes, J.P., K.F. Pasqualoto, V.M. Felli, E.I. Ferreira, and C.A. Brandt. Arch Pharm (Weinheim). [Epub ahead of print]; PMID[20099263].
[Pubmed]. OI_0121-020410.
9. Identification, synthesis, and pharmacological evaluation of tetrahydroindazole based ligands as novel antituberculosis agents. Guo, S., Y. Song, Q. Huang, H. Yuan, B. Wan, Y. Wang, R. He, M.G. Beconi, S.G. Franzblau, and A.P. Kozikowski. J Med Chem. 53(2): p. 649-59; PMID[20000470].
[Pubmed]. OI_0121-020410.
10. Rational design of 5-phenyl-3-isoxazolecarboxylic acid ethyl esters as growth inhibitors of Mycobacterium tuberculosis. a potent and selective series for further drug development. Lilienkampf, A., M. Pieroni, B. Wan, Y. Wang, S.G. Franzblau, and A.P. Kozikowski. J Med Chem. 53(2): p. 678-88; PMID[20000577].
[Pubmed]. OI_0121-020410.
11. Synthesis and antituberculosis activity of novel mefloquine-isoxazole carboxylic esters as prodrugs. Mao, J., H. Yuan, Y. Wang, B. Wan, D. Pak, R. He, and S.G. Franzblau. Bioorg Med Chem Lett. 20(3): p. 1263-1268; PMID[20022500].
[Pubmed]. OI_0121-020410.
12. Determination of the susceptibility of Mycobacterium tuberculosis to pyrazinamide in liquid and solid media assessed by a colorimetric nitrate reductase assay. Syre, H., K. Ovreas, and H.M. Grewal. J Antimicrob Chemother. [Epub ahead of print]; PMID[20118493].
[Pubmed]. OI_0121-020410.
13. Identification of benzofuro[2,3-b]quinoline derivatives as a new class of antituberculosis agents. Yang, C.L., C.H. Tseng, Y.L. Chen, C.M. Lu, C.L. Kao, M.H. Wu, and C.C. Tzeng. Eur J Med Chem. 45(2): p. 602-7; PMID[19926361].
[Pubmed]. OI_0121-020410.